Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases

Starting soon · Phase 2

Conditions studied: Colorectal Cancer Liver Metastases (CRLM), Colorectal Cancer, Liver Metastasis

In brief

This is a prospective, single-center, single-arm exploratory clinical study designed to evaluate the efficacy and safety of hepatic arterial infusion of liposomal irinotecan combined with systemic oxaliplatin and capecitabine as postoperative adjuvant therapy in patients with colorectal cancer liver metastases after radical resection. Eligible participants must have histologically confirmed colorectal cancer liver metastases and have completed radical resection of the colorectal primary tumor and liver metastases within 12 weeks before enrollment. Postoperative imaging must show no residual lesion, recurrence, or extrahepatic metastasis, indicating no evidence of disease. Participants will receive hepatic arterial infusion chemotherapy with liposomal irinotecan plus systemic chemotherapy with oxaliplatin and capecitabine every 21 days for 2 to 4 cycles. After 2 cycles, treatment continuation will be determined by the investigator based on efficacy and tolerability.

Key facts

Study ID

NCT07570914

Run by

Tianjin Medical University Cancer Institute and Hospital

People needed

28

Starts

2026-05-30

Expected to finish

2032-05-30

Last updated by the study team

2026-05-06

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 to 75 years.
• Completion of radical resection of the colorectal primary tumor and liver metastases within 12 weeks before enrollment, with postoperative imaging showing no residual lesion, recurrence, or extrahepatic metastasis, indicating no evidence of disease.
• Histologically confirmed colorectal cancer liver metastases.
• ECOG performance status of 0 or 1.
• Expected survival of at least 3 months.
• Clinical risk score of 3 or higher.
• Adequate bone marrow function, defined as absolute neutrophil count >2 × 10\^9/L, hemoglobin >9.0 g/dL, and platelet count >100 × 10\^9/L.
• Adequate renal function, defined as serum creatinine ≤1.5 × the upper limit of normal or creatinine clearance ≥30 mL/min according to the Cockcroft-Gault formula.
• Adequate hepatic function, defined as serum bilirubin ≤1.5 × the upper limit of normal, transaminases ≤2.5 × the upper limit of normal or ≤5 × the upper limit of normal if liver metastasis is present, and alkaline phosphatase ≤5 × the upper limit of normal.
• Female participants must not be pregnant or breastfeeding. Women of childbearing potential and male participants must use effective contraception during the study and for 6 months after completion of study treatment.
• Good compliance, ability to understand the study procedures, and willingness to sign written informed consent.

You may not qualify if…

• Contraindication to capecitabine, oxaliplatin, or irinotecan.
• Any history of hepatic interventional therapy, including transarterial infusion, hepatic arterial infusion, or transarterial chemoembolization.
• Receipt of adjuvant chemotherapy containing irinotecan after resection of the primary tumor, or receipt of adjuvant therapy without irinotecan with the last dose administered within 3 months before enrollment.
• Dihydropyrimidine dehydrogenase deficiency.
• History of severe cardiovascular disease resulting in inability to tolerate treatment.
• Peripheral neuropathy greater than Grade 1.
• History of another malignancy within the previous 5 years, except cured carcinoma in situ or basal cell carcinoma of the skin.
• History of allogeneic organ transplantation.
• Requirement for renal dialysis.
• Breastfeeding, pregnancy, or inadequate contraception in women of childbearing potential.
• Uncontrolled concomitant disease, including but not limited to severe active or uncontrolled infection, symptomatic congestive heart failure, unstable angina, arrhythmia, uncontrolled diabetes, or psychiatric illness that may affect study compliance.
• Participation in another clinical trial currently or within 4 weeks before enrollment.
• Any condition that, in the investigator's judgment, makes the participant unsuitable for the study.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.